ACAD Stock Analysis: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$22.32
0.06 (0.27%)
▲
5d:
+1.41%
30d:
-0.8%
90d:
-16.4%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
ACAD is down 5.8% this week, but smart money is accumulating calls. Top strike: $25 2026-04-17 with 10 OI. Call ratio: 100% View Scanner →
Strength: 7.9/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ACAD appears deeply undervalued. Market expects -5.6% annual earnings decline despite 86% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: ACAD appears deeply undervalued. Market expects -5.6% annual earnings decline despite 86% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$44.04
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$27.35
18.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $22.32, which is considered fair relative to its 30-day fair value range of $20.81 to $23.59. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.7) compared to its historical average (29.4). Remarkably, the market is currently pricing in an annual earnings decline of 5.6% over the next few years. This pessimistic expectation contrasts with the company's recent 86.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ACAD is in a downtrend. The price is approaching resistance at $22.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACAD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.85 (+42.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACAD is in a downtrend. The price is approaching resistance at $22.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACAD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.85 (+42.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$20.81 -
$23.59
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.7% below Wall St target ($31.85)
Fair Price Analysis
30-Day Fair Range
$20.81 -
$23.59
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$19.89
Resistance Level
$22.89
Current Trend
Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.67
Wall Street Target
$31.85
(+42.7%)
Revenue Growth (YoY)
9.4%
Earnings Growth (YoY)
86.2%
Profit Margin
36.5%
Valuation Discount vs History
-5.6% cheaper
PE vs Historical
24.7 vs 29.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.6%
(market-implied from PE analysis)
1-Year Target
$21.07
(-6%)
2-Year Target
$19.89
(-11%)
3-Year Target
$18.78
(-16%)
3-Yr Target (if PE normalizes)
(PE: 25→29)
$22.37
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.7, Growth: 82.2%)
$75.33
(+238%)
Base:
(SPY PE: 22.4, Growth: 82.2%)
$68.24
(+206%)
Bear:
(PE: 19.0, Growth: 82.2%)
$58.00
(+160%)
📈
Valuation based on Current Earnings
Trailing PE: 9.02 | Current EPS (TTM): $2.30
Bull Case
$11.41
(-46%)
Analyst growth -50.0%, PE expands to 9.9
Base Case
$10.37
(-51%)
Market implied -50.0%, PE stable at 9.0
Bear Case
$14.10
(-33%)
Severe decline -20.0%, PE contracts to 7.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.7 to 29.4
Stabilization Target:
$26.60
(+19.2%)
PE Expansion Potential:
+19.2%
Share & Embed Analysis
Last updated: April 02, 2026 7:22 AM ET
Data refreshes hourly during market hours. Next update: 8:22 AM
Data refreshes hourly during market hours. Next update: 8:22 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Jennifer J Rhodes
SELL
6950 shares
2026-02-09
James Kihara
SELL
4084 shares
2025-11-18
Mark C Schneyer
SELL
10262 shares
2025-11-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 55 HOLD |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
